Loading patent…
AssigneeBristol-Myers Squibb Company
InventorsRay CAMPHAUSEN, Jonathan H. DAVIS, Sharon T. CLOAD, Fabienne M. DENHEZ, Amna SAEED-KOTHE, Dasa LIPOVSEK, Ching-Hsiung Frederick LO, Chee Meng LOW, Bowman MIAO, Tracy S. MITCHELL, Rex A. PARKER, Ginger C. RAKESTRAW, Katie A. RUSSO, Doree F. SITKOFF
Estimating the term…
The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.
An isolated nucleic acid molecule encoding a polypeptide comprising a fibronectin type III tenth (10Fn3) domain wherein the 10Fn3 has a BC, DE and FG loop, and wherein the BC loop comprises SEQ ID NO:14, the DE comprises SEQ ID NO:25 and the FG loop comprises SEQ ID NO:37, and wherein the polypeptide binds PCSK9.
An isolated nucleic acid molecule encoding a polypeptide comprising a 10Fn3 domain wherein the polypeptide comprises SEQ ID NO:82, and wherein the polypeptide binds PCSK9.
A method of treating a PCSK9-related disease or disorder in a subject comprising administering an effective amount of a polypeptide comprising a fibronectin type III tenth (10Fn3) domain wherein the 10Fn3 has a BC, DE and FG loop, and wherein the BC loop comprises SEQ ID NO:14, the DE comprises SEQ ID NO:25 and the FG loop comprises SEQ ID NO:37, and wherein the polypeptide binds PCSK9.
A method of treating a PCSK9-related disease or disorder in a subject comprising administering an effective amount of a polypeptide comprising a 10Fn3 domain wherein the isolated polypeptide comprises SEQ ID NO:82, and wherein the isolated polypeptide binds PCSK9.
Dependencies are inferred from the claim text.